Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2024-01-21 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
独立董事专门会议关于第四届董事会第三十次会议相关事项的审查意见
Board/Management Information Classification · 95% confidence The document is a formal announcement from the independent directors of Beijing Kangle Weishi Biotechnology Co., Ltd. regarding their review and opinion on a specific board meeting agenda item related to a credit application and related party guarantee. It includes legal assurances about the accuracy and completeness of the announcement. The content focuses on board-level review and approval of corporate actions, specifically related to financing and guarantees, but it is not a full financial report or earnings release. It is not a report publication announcement or certification letter but a formal board/management information disclosure about a specific corporate governance matter. Therefore, the document fits best under 'Board/Management Information' (MANG). The document length and content confirm it is not a full report but a governance-related announcement.
2024-01-21 Chinese
投资者关系活动记录表
Regulatory Filings Classification · 95% confidence The document is titled as an "Investor Relations Activity Record" from Beijing Kanglevest Biotech Co., Ltd. It contains a Q&A format discussing company policies, product strategies, market conditions, and investor relations activities. There is no financial data, no formal financial statements, no audit information, no voting results, no executive changes, no legal proceedings, no merger or acquisition details, and no regulatory certifications. The document is a record of investor relations activities and discussions rather than a formal report or announcement. It is not a report publication announcement since it contains substantive content rather than just a notice. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement and investor relations communication that does not fit other specific categories.
2024-01-21 Chinese
第四届董事会第三十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Beijing Kangle Weishi Biotechnology Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and compliance with legal and regulatory requirements. The content focuses on board decisions such as changes in fundraising accounts, credit applications, and stock incentive plan conditions. There is no financial data or detailed financial performance analysis, nor is it a transcript or presentation. It is clearly a Board/Management Information announcement about board meeting resolutions and decisions.
2024-01-21 Chinese
关于变更部分募集资金专户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Beijing Kangle Weishi Biotechnology Co., Ltd. regarding the change of some fundraising special accounts. It details the company's board and supervisory meetings approving the change, the background of the fundraising, the management of the funds, and the specifics of transferring the funds to a new bank account. The document does not contain financial statements or detailed financial performance data but rather focuses on the administrative and procedural update about the fundraising accounts. It is a regulatory announcement about capital management and does not qualify as a full financial report or earnings release. Given the content and length (2485 characters), it fits best under Capital/Financing Update (CAP).
2024-01-21 Chinese
第四届监事会第二十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Beijing Kangle Weishi Biotechnology Co., Ltd. It details the convening and attendance of the meeting, the agenda items discussed, and the voting results on various company matters such as changes to fundraising accounts, bank credit applications, and stock incentive plan conditions. There is no financial data or detailed financial report included. The document is a formal announcement of board/committee decisions rather than a full report or financial statement. It fits best under Board/Management Information (MANG) as it relates to internal governance decisions and supervisory board resolutions.
2024-01-21 Chinese
2024年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of resolutions passed at an extraordinary general meeting (EGM) of Beijing 康乐卫士生物技术股份有限公司 regarding the issuance and listing of H shares on the Hong Kong Stock Exchange. It includes detailed voting results, descriptions of proposals related to share issuance, listing plans, amendments to company articles, governance changes, appointment of auditors, and authorization of board members to handle listing matters. The document is not a financial report, audit report, or earnings release, but rather a formal announcement of shareholder meeting decisions and voting outcomes. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is substantial and contains full voting results and resolutions, not just a brief notice or a report publication announcement. Therefore, the correct classification is DVA with high confidence.
2024-01-14 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.